The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Atazanavir Teva 300 mg Capsules, hard

300 milligram(s) Capsule, hard

Teva B.V.PA1986/028/003

Main Information

Trade NameAtazanavir Teva 300 mg Capsules, hard
Active SubstancesAtazanavir sulfate
Strength300 milligram(s)
Dosage FormCapsule, hard
Licence HolderTeva B.V.
Licence NumberPA1986/028/003

Group Information

ATC CodeJ05AE Protease inhibitors
J05AE08 atazanavir


Licence Issued30/10/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back